Nitrazepam

Concomitant use increases risk of hypotension, respiratory depression, profound sedation, coma, and death. Reserve for patients where alternative treatments are inadequate.

Concomitant use increases risk of hypotension, respiratory depression, profound sedation, coma, and death. Reserve for patients where alternatives are inadequate.

Concomitant use increases risk of respiratory depression, profound sedation, coma, and death due to additive CNS depressant effects.

Concomitant use with benzodiazepines can increase risk of hypotension, respiratory depression, profound sedation, coma, and death. Concomitant prescribing should be reserved for patients with inadequate alternatives.

Benzodiazepines are incompatible with hyaluronidase.

Incompatible with hyaluronidase; physical or chemical incompatibility reported.

CNS depressants that increase risk of hypotension, respiratory depression, profound sedation, coma, and death. Concomitant use should be reserved for patients with inadequate alternatives.

Concomitant use increases risk of hypotension, respiratory depression, profound sedation, coma, and death due to additive CNS depressant effects.

Concomitant use may result in profound sedation, respiratory depression, coma, or death.

Additive CNS depression increases risk of hypotension, respiratory depression, profound sedation, coma, and death. Concomitant use should be reserved for inadequate alternative options.

Concomitant use increases risk of hypotension, respiratory depression, profound sedation, coma, and death. Reserve for patients where alternatives are inadequate.

Concomitant use increases risk of hypotension, respiratory depression, profound sedation, coma, and death due to additive CNS depressant effects.

Concomitant use increases risk of hypotension, respiratory depression, profound sedation, coma, and death. Reserve for patients where alternatives are inadequate.

Concomitant use increases risk of respiratory depression, profound sedation, coma, and death due to additive CNS depressant effects.

Additive CNS depressant effects increasing risk of hypotension, respiratory depression, profound sedation, coma, and death.

Additive CNS depressant effects increase risk of respiratory depression, profound sedation, coma, and death.

Concomitant use increases risk of respiratory depression, profound sedation, coma, and death due to additive CNS depressant effects.

Concomitant use increases risk of respiratory depression, profound sedation, coma, and death due to additive CNS depressant effects.

Concomitant use increases risk of respiratory depression, profound sedation, coma, and death due to additive CNS depressant effects.

Additive CNS depressant effects increase risk of respiratory depression, profound sedation, coma, and death.

Additive CNS depressant effects increase risk of hypotension, respiratory depression, profound sedation, coma, and death.

Concomitant use causes additive CNS depressant effects, increasing risk of respiratory depression, sedation, and overdose.

Additive CNS depressant effects can increase risk of hypotension, respiratory depression, profound sedation, coma, and death.

Additive CNS depression increasing risk of hypotension, respiratory depression, profound sedation, coma, and death.

Concomitant use increases risk of respiratory depression, profound sedation, coma, and death due to additive CNS depressant effects.

Concomitant use increases risk of hypotension, respiratory depression, profound sedation, coma, and death due to additive CNS depression.

Concomitant use increases risk of respiratory depression, profound sedation, coma, and death due to additive CNS depressant effects.

Additive CNS depressant effect increases risk of hypotension, respiratory depression, profound sedation, coma, and death.

Concomitant use increases risk of hypotension, respiratory depression, profound sedation, coma, and death due to additive CNS depressant effects.

Antagonistic effects with decreased phenylephrine blood pressure effect.

May increase anesthetic/sedative effects and cardiorespiratory depression; can result in pronounced decreases in blood pressure and cardiac output.

In combination with opioids, may reduce induction dose requirements and increase anesthetic/sedative effects with pronounced decreases in blood pressure and cardiac output.

Additive CNS depression increases risk of hypotension, respiratory depression, profound sedation, coma, and death.

CNS depressants that increase risk of hypotension, respiratory depression, profound sedation, coma, and death when combined with sufentanil.

Additive CNS depressant effects increase risk of respiratory depression, profound sedation, coma, and death.

Altered mental status observed in patients taking GATTEX (teduglutide) and benzodiazepines. Monitor for adverse reactions and may require dosage reduction.

Additive sedative effects with carisoprodol. Caution should be exercised when used concomitantly.

Triazolobenzodiazepines and Other Related Benzodiazepines: Midazolam Alprazolam Triazolam Temazepam Nitrazepam Lorazepam Use With Caution No Dose Adjustment Midazolam : When oral midazolam is co-administered with clarithromycin, dose adjustments may be necessary and possible prolongation and intensity of effect should be anticipated [see Warnings and Precautions (5.4) and Pharmacokinetics (12.3) ] . Temazepam, Nitrazepam, Lorazepam : For benzodiazepines which are not metabolized by CYP3A (e.g., temazepam, nitrazepam, lorazepam), a clinically important interaction with clarithromycin is unlikely.

Benzodiazepines decrease the amount of desflurane needed to produce anesthesia. Adjust dose accordingly.

May increase certain actions or side effects of anticholinergic drugs including dicyclomine hydrochloride.

Increased exposure of benzodiazepines due to CYP3A4 inhibition by diltiazem.

May potentiate CNS depressant effects of diphenoxylate hydrochloride and atropine sulfate. Monitor for CNS adverse reactions.

Concomitant use may increase sedation. Closely monitor for sedation with concomitant use.

Concomitant use may increase risk of CNS depression including somnolence.

Lofexidine potentiates CNS depressant effects of benzodiazepines.

Lofexidine potentiates CNS depressant effects of benzodiazepines.

Sedative effects of metaxalone and benzodiazepines may be additive. Exercise caution and monitor for respiratory depression and sedation.

Concomitant use increases impairment of cognitive and motor skills. Avoid concomitant use.

Additive drowsiness and CNS depression reported with concurrent use. Caution advised.

May potentiate orthostatic hypotension and sedation.

Omeprazole can prolong elimination of benzodiazepines. Monitor and determine need for dose adjustments.

Omeprazole and sodium bicarbonate can prolong elimination of benzodiazepines. Monitor for possible dose adjustments.

CNS depressants that may increase CNS depression when used with FYCOMPA. Patients should limit activity until experienced with concomitant use.

Concomitant use may potentiate CNS depression including dizziness and cognitive adverse reactions.

Concomitant use with CNS depressants may potentiate CNS depression such as dizziness or cognitive adverse reactions.

Sedative effect of remimazolam besylate can be accentuated by other benzodiazepines. Dose titration required with continuous vital sign monitoring.

Benzodiazepines decrease the MAC of sevoflurane; sevoflurane is compatible with benzodiazepines as commonly used in surgical practice.

CNS depressants with potentially additive sedative effects. Monitor for excess sedation.

CNS depressants that may cause additive CNS depressant effects including sedation when combined with tizanidine; monitor for excess sedation.

CNS depressants; concomitant use may cause additive CNS depressant effects including sedation; monitor for excess sedation.

Formal study showed benzodiazepines do not affect mexiletine plasma concentrations.

No dose adjustment needed when co-administered with montelukast sodium.

No dose adjustment needed when co-administered with montelukast sodium.

Benzodiazepines have no effect on rufinamide concentration.

Temazepam Nitrazepam Lorazepam No Dose Adjustment Temazepam, Nitrazepam, Lorazepam : For benzodiazepines which are not metabolized by CYP3A (e.g., temazepam, nitrazepam, lorazepam), a clinically important interaction with clarithromycin is unlikely.